Concepedia

S. Qin

SQ

Statistics

Publications

2

Citations

289

H-Index

2

Active since

2022

Affiliations

Fudan University(Current)

Hunan Cancer Hospital

Zhongshan Hospital

National Taiwan University Hospital

Nanjing University of Chinese Medicine

S. Qin is an author at Fudan University specializing in cancer therapeutics, radiation oncology, and hepatology.

Top concepts

Publications per year

2022–2022

2

Publications

2

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

R.S. Finn, Masatoshi Kudo, Philippe Merle et al. · Annals of Oncology · 2022 · 192 citations

, , +9

LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

S. Qin, L.S. Chan, Shanzhi Gu et al. · Annals of Oncology · 2022 · 97 citations

, , +9

1–2 of 2